用户名： 密   码：
注册 | 忘记密码？
药品详细

Cefmenoxime(头孢甲肟)

化学结构式图
中文名
头孢甲肟
英文名
Cefmenoxime
分子式
C16H17N9O5S3
化学名
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
分子量
Average: 511.558
Monoisotopic: 511.051476769
CAS号
65085-01-0
ATC分类
J01D Other Beta- lactam Antibacterials
药物类型
small molecule
阶段
approved
商品名
Bestcall;Cefmax;Tacef;
同义名
Cefmenoxima [INN-Spanish];Cefmenoxime hydrochloride;Cefmenoximum [INN-Latin];
基本介绍

Cefmenoxime is a third-generation cephalosporin antibiotic. [Wikipedia]

生产厂家
  • Tap pharmaceutical products inc
封装厂家
参考
Synthesis Reference Not Available
General Reference
  1. Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T: [Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis] Jpn J Antibiot. 1995 May;48(5):602-9. Pubmed
  2. Paladino JA, Fell RE: Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother. 1994 Mar;28(3):384-9. Pubmed
  3. Duncker GI, Reich U, Krausse R: Cefmenoxime in corneal organ culture. Ophthalmologica. 1994;208(5):262-6. Pubmed
  4. Tsuchiya K, Kondo M, Kida M, Nakao M, Iwahi T, Nishi T, Noji Y, Takeuchi M, Nozaki Y: Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1981 Jan;19(1):56-65. Pubmed
剂型
规格
化合物类型
Type small molecule
Classes Not Available
Substructures Not Available
适应症
antibacterials 抗细菌;
药理
Indication Used to treat female gynecologic and obstetric infections caused by susceptible aerobic (including the gonococcus) and anaerobic bacteria.
Pharmacodynamics Cefmenoxime is a semisynthetic beta-lactam cephalosporin antibiotic with activity similar to that of cefotaxime. It has broad spectrum activity against Gram positive and Gram negative bacteria.
Mechanism of action The bactericidal activity of cefmenoxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefmenoxime is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases.
Absorption Bioavailability is approximately 100% following intramuscular injection.
Volume of distribution Not Available
Protein binding 50-70%
Metabolism
Not appreciably metabolized.
Route of elimination Not Available
Half life 1 hour
Clearance Not Available
Toxicity Information on cefmenoxime overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways Not Available
理化性质
Properties
State solid
Experimental Properties
Property Value Source
logP -1.3 Not Available
Predicted Properties
Property Value Source
water solubility 4.46e-01 g/l ALOGPS
logP -0.13 ALOGPS
logP -0.83 ChemAxon
logS -3.1 ALOGPS
pKa (strongest acidic) 3.04 ChemAxon
pKa (strongest basic) 4.14 ChemAxon
physiological charge -1 ChemAxon
hydrogen acceptor count 11 ChemAxon
hydrogen donor count 3 ChemAxon
polar surface area 190.81 ChemAxon
rotatable bond count 8 ChemAxon
refractivity 133.51 ChemAxon
polarizability 47.04 ChemAxon
药物相互作用
食物相互作用
Not Available

返回 | 收藏